Document Detail

PRAMEing a picture of differentiation therapy for AML?
MedLine Citation:
PMID:  23532884     Owner:  NLM     Status:  Publisher    
Addition of retinoic acid to chemotherapy improves survival of patients with acute myeloid leukemia. This effect is more pronounced in leukemias that express high levels of PRAME. PRAME is an inhibitor of retinoic acid signaling, which may prove to be an important marker for retinoic acid response.
Robert L Redner
Related Documents :
7574484 - The envelope of mycobacteria.
128354 - Studies on the linkage between teichoic acid and peptidoglycan in a bacteriophage-resis...
7076624 - Major sites of metal binding in bacillus licheniformis walls.
2483524 - Saccharides of seven pseudomonas aeruginosa immunotypes.
24882914 - Self-structuring foods based on acid-sensitive low and high acyl mixed gellan systems t...
15788404 - Biochemical and molecular characterization of a novel choline-specific glycerophosphodi...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-3-26
Journal Detail:
Title:  Clinical cancer research : an official journal of the American Association for Cancer Research     Volume:  -     ISSN:  1078-0432     ISO Abbreviation:  Clin. Cancer Res.     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-3-27     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9502500     Medline TA:  Clin Cancer Res     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
University of Pittsburgh Cancer Institute, University of Pittsburgh.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Aspiration pneumonia in dogs: pathophysiology, prevention, and diagnosis.
Next Document:  Classifying MMR variants: time for revised nomenclature in Lynch syndrome.